Salute e Benessere

Basilea receives USD 25 million funding under BARDA agreement to continue to…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services,...
Nasdaq GlobeNewswire
16/09/2025

MAGIC IS ON ITS WAY WITH SELFRIDGES AND DISNEY

'A Most Magical Christmas' is inspired by timeless Disney stories and characters, bringing a sense of nostalgia and playfulness to a series of extraordinary and unforgettable in-store and online experiences. Visitors are invited to embrace the joys of childhood, immersing themselves in an expression of the timeless Disney adage "You're never too old to be young". 'A Most Magical Christmas' is inspired by timeless Disney stories and characters, bringing a sense of nostalgia and…
PR Newswire
16/09/2025

People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted…

Results from a real-world survey suggest that semaglutide for weight management (Wegovy ® ) helped suppress food noise – unwanted and intrusive thoughts about food – in addition to its established effect on weight loss 1 The number of people who reported experiencing constant thoughts about food throughout the day declined by 46% after starting treatment with Wegovy ®1 The majority of respondents reported improved mental health (64%) and healthier habits (80%) while taking Wegovy ®1 ...
Nasdaq GlobeNewswire
16/09/2025

Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade…

Bispecific Antibodies in Oncology Market Summary Bispecific Antibodies in Oncology Market Summary Discover which indication is expected to grab the major bispecific antibodies in oncology market share @Bispecific Antibodies in Oncology Market Report Key Factors Driving the Growth of the Bispecific Antibodies in Oncology Market Rising Cancer Incidence The increasing global prevalence of cancer is a significant driver for the bispecific antibodies market. The WHO/IARC...
PR Newswire
15/09/2025

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc. (collectively, “Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that it has filed a lawsuit against Inspire Medical Systems, Inc. (“Inspire”) alleging that the Inspire...
Nasdaq GlobeNewswire
15/09/2025

Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates…

PAINWeek is a prestigious event that brings together thousands of leading clinicians, researchers, educators, and potential pharmaceutical partners in the field of pain medicine, offering a rare chance to connect, share ideas, and highlight new approaches. At the conference, Dr. Pergolizzi presented data from a narrative review highlighting the limitations of plant-derived CBD oils in treating chronic pain and the urgent need for regulated, long-acting synthetic CBD therapies. In parallel…
PR Newswire
15/09/2025

LBB Specialties and Imerys Form Specialty Distribution Partnership in North…

This partnership enhances LBBS's portfolio, expanding access to innovative, sustainability-driven mineral technologies. By combining Imerys' globally recognized expertise in mineral science with LBBS's market reach and customer support, the collaboration strengthens resources for formulators facing complex technical and regulatory challenges. This partnership enhances LBBS's portfolio, expanding access to innovative, sustainability-driven mineral technologies. By combining Imerys' globally...
PR Newswire
15/09/2025

Diphtheria Tetanus Pertussis (DTP) Vaccine Market Driven by Rising Immunization…

The expansion is largely attributed to increasing vaccination rates, supportive healthcare policies, and technological advancements in vaccine production, highlighting the market's critical role in global immunization efforts and disease prevention strategies. The expansion is largely attributed to increasing vaccination rates, supportive healthcare policies, and technological advancements in vaccine production, highlighting the market's critical role in global immunization efforts and…
PR Newswire
15/09/2025

Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST…

SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEMGhent, Belgium, 15 September 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a subscription request notice in accordance with the terms of the share subscription facility…
Nasdaq GlobeNewswire
15/09/2025

Guerbet : Adjustment of 2025 full-year financial targets

Adjustment of 2025 full-year financial targets Villepinte, 15 September 2025, 5.45 p.m.:Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to its financial targets for full-year 2025.Business activity in France continues to be impacted by supply reforms. In the United States, an unfavourable shift in the customer mix, with distributors representing a higher proportion...
Nasdaq GlobeNewswire
15/09/2025

Cancer Gene Therapy Market Size Worth US$ 19.97 Billion by 2033, with a 19.8%…

Furthermore, the market is experiencing significant growth due to increased research and development activities, advancements in product technologies, and the introduction of new products by key industry players. This progress is propelling the healthcare infrastructure to unprecedented levels. For instance, in April 2023, an improved gene editing method was introduced based on special cell-penetrating peptides, representing a significant advancement in cell and gene therapies. This technique…
PR Newswire
15/09/2025

Neuromodulation Market worth US$10.68 billion by 2030 with 9.4% CAGR |…

Browse in-depth TOC on "Neuromodulation Market" Browse in-depth TOC on "Neuromodulation Market" 400 - Tables 45 - Figures 350 - Pages By technology,the neuromodulation technology market is categorized into two main types: internal neuromodulation and external neuromodulation. The internal neuromodulation segment held the largest market share in 2024. Internal neuromodulation has an advantage due to its ability to deliver targeted, long-term therapy for chronic…
PR Newswire
15/09/2025

Immunohistochemistry Market worth US$5.14 billion by 2030 with 7.6% CAGR |…

Browse in-depth TOC on "Immunohistochemistry Market" Browse in-depth TOC on "Immunohistochemistry Market" 666 - Tables 63 - Figures 490 - Pages By offering,the immunohistochemistry market is segmented into antibodies, reagents, kits, equipment, and software. Kits were the fastest-growing segment during the forecast period 2025-2030. This surge is driven by a significant market shift among end-users, including high-volume diagnostic laboratories, hospitals, and research...
PR Newswire
15/09/2025

Pediatric Clinical Trials Market Size Worth US$ 31.77 Billion by 2033, with a…

Nirsevimab (Beyfortus) is a breakthrough monoclonal antibody approved to prevent Respiratory Syncytial Virus (RSV) in infants and young children, providing protection throughout the RSV season with a single injection. Clinical trials demonstrated a 70-75% reduction in RSV-related hospitalizations among preterm and term infants. Beyfortus exemplifies how pediatric trials are delivering life-saving therapies. Nirsevimab (Beyfortus) is a breakthrough monoclonal antibody approved to prevent...
PR Newswire
15/09/2025

Diagnostic Imaging Market worth US$32.90 billion by 2030 with 4.4% CAGR |…

Browse in-depth TOC on "Diagnostic Imaging Market" Browse in-depth TOC on "Diagnostic Imaging Market" 399 - Tables 55 - Figures 393 - Pages By product,the global diagnostic imaging market is divided into several segments: CT scanners, X-ray imaging systems, ultrasound systems, MRI systems, nuclear imaging systems, and mammography systems. The MRI systems segment is expected to register the highest growth rate during the forecast period. The demand for enhanced MRI scans is...
PR Newswire
15/09/2025

Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for…

Approval Highlights CP-9's Safety and Quality Approval Highlights CP-9's Safety and Quality According to the FDA filing, CP-9 is authorized for use at levels up to 10⁹ colony-forming units (CFUs) per-serving in a wide range of food and beverage products: The newly approved CP-9 was a finalist at the 2023 NutraIngredients Awards and has been studied for its role in gut health and immune regulation. With FDA GRAS status, CP-9 expands Glac Biotech's portfolio and is expected to serve the...
PR Newswire
15/09/2025

LabConnect and OmniScience to Deliver First Agentic AI Solution for Real-Time…

Faster Decisions and Smarter Oversight with LabConnect + Vivo Clinical trial lab data is often siloed, complex, and delayed. This causes slow decision-making and introduces risk. By combining LabConnect's expertise in central lab testing and data management with OmniScience's Vivo platform, trial sponsors can now unify fragmented lab datasets, automate oversight, and surface risk signals that accelerate trial timelines and improve outcomes. Faster Decisions and Smarter Oversight with...
PR Newswire
15/09/2025

Conceivable Life Sciences Secures $50 Million Series A

Funding supports U.S. market launch of AURA, World’s first AI-powered automated IVF lab NEW YORK, Sept.15, 2025(GLOBE NEWSWIRE) -- Conceivable Life Sciences today announced its $50 million Series A financing to accelerate the development and commercialization of the world's first AI-powered automated IVF laboratory. The funding will support the company's mission to make this Nobel Prize-winning therapy more accessible, scalable, and effective at delivering improved pregnancy results...
Nasdaq GlobeNewswire
15/09/2025

Kolmar Korea Advances 'Clean Beauty' with Breakthroughs from Eco-Friendly…

These innovations have earned international recognition. The paper tube and paper stick achieved a "grand slam" in design by winning the world's top three design awards—IDEA, iF Design Award, and Red Dot Design Award. The one-hand pump paper pack also won a Red Dot Design Award this year, further validating the global competitiveness of Kolmar Korea's eco-friendly packaging. These innovations have earned international recognition. The paper tube and paper stick achieved a "grand…
PR Newswire
15/09/2025

KFSHRC Reduces Emergency Department Inpatient Bed Waiting Time by 75%

To achieve this transformation, KFSHRC implemented a comprehensive, data-driven process reengineering program aimed at addressing the root causes of delays across the entire patient journey from entry to the emergency department through inpatient admission. The initiative was supported by the AI enabled Patient Flow & Capacity Command Centre, which tracks patient flow in real time and forecasts potential bottlenecks before they occur.The primary role of process re-engineering was to...
Nasdaq GlobeNewswire
15/09/2025

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1…

Oral semaglutide (Rybelsus ® ) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular benefits 1 This approval is based on results from the SOUL clinical trial, where oral semaglutide (Rybelsus ® ) reduced cardiovascular death, heart attack and stroke by 14% versus placebo, when added to standard of care, in adults with type 2 diabetes at high cardiovascular risk 1 In addition, new results from SOUL will be presented at one of the largest diabetes...
Nasdaq GlobeNewswire
15/09/2025

FutureCeuticals Files Lawsuit Against NeuroRush Owner for Patent Infringement…

"Aura Scientific's ingredient NeuroRush offers nothing new, simply 'piggybacking' on FutureCeuticals' renowned, robust science, and patented discoveries in the coffee fruit sector, with infringement as the clear consequence. Indeed, this is among the most open and willful infringements we've ever seen, harming not only us, but our many licensees currently selling products containing our genuine ingredients, CognatiQ® and NeuroFactor®," J. Randal Wexler, FutureCeuticals' Vice President…
PR Newswire
15/09/2025

AMO Pharma Reports Long-Term Safety Data from REACHCDM-X Study of AMO-02 in…

"We are pleased to share new findings that reflect the experience of patients treated with AMO-02 for almost four full years in our REACHCDM-X open-label extension study. These results include new insights indicating that AMO-02 continues to have an advantageous safety profile, and we were especially encouraged by the low rate of hospitalizations observed during the study," said Mike Snape, Chief Executive Officer at AMO Pharma. "We look forward to meeting with the FDA later this…
PR Newswire
15/09/2025

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the U.S. Department of Defense (DoD) has awarded a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). This funding builds on Tiziana’s strategy to expand the therapeutic potential of its intranasal anti-CD3...
Nasdaq GlobeNewswire
15/09/2025
Altri  Comunicati